Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
Advanced Biliary Tract Adenocarcinoma
DRUG: Sunitinib
Time to progression, 12months
Safety profile, 12 months|Response rate, 12 months|Duration of response, 12 months|Overall survival, 12 months|Correlative analyses: EGFR mutational analysis, EGFR immunohistochemical staining, RAS mutational analysis, KIT, PDGFRA, PDGFRB, Beta-Catenin (CTNNB1) mutations, 12 months
Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: multicenter, multinational study